AyuVis is a clinical-stage pharmaceutical company developing a proprietary immunomodulation technology based on small-molecule drug designs that facilitate and modulate a unique profile of immune cells. The compounds quieten hyperinflammation and simultaneously balance the immune response with adequate disease clearance and specific tissue repair. The company’s macrophage-modulating platform produced several lead candidates for different disease indications. Our lead compound, AVR-48, is entering clinical trials to prevent a pediatric neonatal lung disease for which there are no FDA-approved therapies and existing off-label treatments are not effective. AVR-48 binds to immune cell receptors TLR2/4 and CD163, producing a unique immune cell lineage that balances innate and adaptive immune activation while inhibiting inflammatory cytokine production. AyuVis’ vision is to save and improve the lives of suffering patients globally, including those from underserved populations globally.